“Small” Intestinal Immunopathology Plays a “Big” Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor
Kale SD, Mehrkens BN, Stegman MM, Kastelberg B, Carnes H, McNeill RJ, Rizzo A, Karyala SV, Coutermarsh-Ott S, Fretz JA, Sun Y, Koff JL, Rajagopalan G. “Small” Intestinal Immunopathology Plays a “Big” Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor. Frontiers In Immunology 2020, 11: 1311. PMID: 32676080, PMCID: PMC7333770, DOI: 10.3389/fimmu.2020.01311.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCells, CulturedCoronavirus InfectionsCOVID-19Cytokine Release SyndromeCytokinesHLA-DR3 AntigenInterferon-gammaInterleukin-17Intestine, SmallJanus Kinase InhibitorsLymphocyte ActivationMiceMice, KnockoutNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesT-Lymphocytes, Helper-InducerConceptsSmall bowel pathologyMultiple organ dysfunctionIL-17A deficiencySmall intestinal immunopathologyCytokine release syndromeToxic shock syndromeBowel pathologyIntestinal immunopathologyRelease syndromeChimeric antigen receptor T-cell therapySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Immune check point inhibitorsHLA-DR3 transgenic miceRespiratory syndrome coronavirus 2HLA-DR3 miceIFN-γ deficiencyCheck point inhibitorsSyndrome coronavirus 2T-cell therapyJAK 1/2 inhibitorJanus kinase inhibitorSmall intestinal tissueCoronavirus disease 2019T cell activation